Ali Tehrani - 15 Jul 2021 Form 4 Insider Report for Zymeworks Inc.

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: N/A
Reported as of: 15 Jul 2021
Net transaction value: -$1,427,794
SEC form: 4
Accepted by SEC: 16 Jul 2021, 21:30:18 UTC
Prior SEC filing: 13 Jul 2021
Source filing: View source filing
Reporting owner signature: /s/ Daniel Dex, Attorney-in-Fact

Key filing fact

Ali Tehrani filed Form 4 for Zymeworks Inc. on 16 Jul 2021.

Key facts

This page summarizes Ali Tehrani's Form 4 filing for Zymeworks Inc..
6 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 16 Jul 2021, 21:30.

Change

Previous filing in this sequence was filed on 13 Jul 2021.
Current net transaction value: -$1,427,794.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ZYME transaction

Common Shares

Options Exercise

Transaction value: $16,231
Shares: +3,800
Change %: +1.5%
Price: $4.27
Shares after: 264,125
Date: 15 Jul 2021
Ownership: Direct
Footnotes: F1, F2

ZYME transaction

Common Shares

Sale

Transaction value: $136,800
Shares: -3,800
Change %: -1.4%
Price: $36.00^*
Shares after: 260,325
Date: 15 Jul 2021
Ownership: Direct
Footnotes: F1, F3

ZYME transaction

Common Shares

Options Exercise

Transaction value: $175,651
Shares: +41,191
Change %: +16%
Price: $4.26
Shares after: 301,516
Date: 16 Jul 2021
Ownership: Direct
Footnotes: F1, F4

ZYME transaction

Common Shares

Sale

Transaction value: $1,482,876
Shares: -41,191
Change %: -14%
Price: $36.00^*
Shares after: 260,325
Date: 16 Jul 2021
Ownership: Direct
Footnotes: F1, F3

ZYME holding

Common Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 55,511
Date: 15 Jul 2021
Ownership: Held by spouse

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ZYME transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value: $0
Shares: -3,800
Change %: -8.4%
Price: $0.000000
Shares after: 41,191
Date: 15 Jul 2021
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 3,800
Exercise price: $4.27
Footnotes: F1, F2, F5

ZYME transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value: $0
Shares: -41,191
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 16 Jul 2021
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 41,191
Exercise price: $4.26
Footnotes: F1, F4, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

Pursuant to a 10b5-1 plan entered into May 13, 2021.

Footnote F2

The exercise price of the stock option is CAD5.37. The U.S. dollar equivalent of the exercise price is $4.2713 using the Bank of Canada exchange rate for July 15, 2021 (CAD1.00 = $0.7954).

Footnote F3

All shares were sold at $36.00 per share.

Footnote F4

The exercise price of the stock option is CAD5.37. The U.S. dollar equivalent of the exercise price is $4.2643 using the Bank of Canada exchange rate for July 16, 2021 (CAD1.00 = $0.7941).

Footnote F5

Stock options vest as follows: (i) 25% of underlying shares on first anniversary of grant date of January 1, 2012 and (ii) remainder of underlying shares in 36 equal monthly installments on the last day of month following first anniversary of grant date.